|Bid||4.0900 x 1800|
|Ask||4.1000 x 47300|
|Day's range||4.0700 - 4.3020|
|52-week range||1.9400 - 6.2500|
|Beta (5Y monthly)||1.93|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.17|
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
Shares of MannKind (NASDAQ: MNKD), a company working to develop inhaled therapeutics, were down 18% as of 11:59 a.m. EDT on Monday after an inspection issue derailed its hopes of approval for Tyvaso DPI, a lung disease therapy it developed with United Therapeutics (NASDAQ: UTHR). According to United Therapeutics' Securities and Exchange Commission filings, it owns two patents for treating PAH through inhalation that expire in 2024. The Food and Drug Administration's complete response letter didn't cite issues with MannKind's operations or even the clinical data submitted by the two companies.
By Sam Boughedda